Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: A meta-analysis

Nuclear Medicine Communications

Volumn 34, Issue 8, 2013, Pages 758-766

  Deng, Sheng Ming ^a,b   Zhang, Bin ^a   Wu, Yi Wei ^a   Zhang, Wei ^a   Chen, Yin Yin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

11C MET PET; DSCE MRI; Glioma recurrence; Meta analysis

Indexed keywords

METHIONINE C 11;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; HUMAN; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

CONTRAST MEDIA; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; METHIONINE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE;

EID: 84879931204     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328361f598     Document Type: Article

References (33)

1. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000; 41:1861-1867.
2. Little MP, Rajaraman P, Curtis RE, Devesa SS, Inskip PD, Check DP, Linet MS. Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ 2012; 344:e1147.
3. Mullins ME, Barest GD, Schaefer PW, Hochberg FH, Gonzalez RG, Lev MH. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. Am J Neuroradiol 2005; 26:1967-1972.
4. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol 1998; 19:407-413.
5. Bénard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003; 33:148-162.
6. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Clinical usefulness of 11C-MET PET and 201Tl SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998; 38: 342-348.
7. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005; 32:39-51.
8. Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010; 112:758-765.
9. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 10:25-37.
10. Whiting PF,Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6:9-16.
11. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6:31.
12. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery in malignant glioma. Ann Nucl Med 2004; 18:291-296.
13. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, Ohata K. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008; 49:694-699.
14. Nakajima T, Kumabe T, Kanamori M, Saito R, Tashiro M, Watanabe M, Tominaga T. Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography. Neurol Med Chir (Tokyo) 2009; 49:394-401.
15. Okamoto S, Shiga T, Hattori N, Kubo N, Takei T, Katoh N, et al. Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med 2011; 25:213-220.
16. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 2011; 81:1049-1058.
17. Li DL, Xu YK, Wang QS, Wu HB, Li HS. 11C-methionine and 18Ffluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Chin Med J (Engl) 2012; 125:91-96.
18. Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 2012; 37:158-163.
19. Shishido H, Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Tamiya T. Diagnostic value of 11C-methionine (MET) and 18F-fluorothymidine (FLT) positron emission tomography in recurrent high-grade gliomas: differentiation, from treatment-induced tissue necrosis. Cancers 2012; 4:244-256.
20. Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, Cha S. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging. Radiology 2009; 253:486-496.
21. Gasparetto EL, Pawlak MA, Patel SH, Huse J, Woo JH, Kreiza J, et al. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 2009; 250:887-896.
22. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging measurements. Am J Neuroradiol 2009; 30:552-558.
23. Ozsunar Y, Mullins ME, Kwong K, Hochberg FH, Ament C, Schaefer PW, et al. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 2010; 17:282-290.
24. Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maeavilla KR. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010; 52:297-306.
25. Fink JR, Carr RB, Matsusue E, Iyer RS, Rockhill JK, Haynor DR, Maravilla KR. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging 2012; 35:56-63.
26. Würker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996; 23:583-586.
27. Yamamoto T, Nishizawa S, Maruyama I, Yoshida M, Tsuchida T,Waki A, et al. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumours: FDG PET study. Ann Nucl Med 2001; 15:103-109.
28. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96:191-197.
29. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT. Diagnosis of recurrent brain tumor: value of 201Tl SPECTversus 18F-fluorodeoxyglucose PET. Am J Roentgenol 1994; 163:1459-1465.
30. Lupo JM, Cha S, Chang SM, Nelson SJ. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. Am J Neuroradiol 2005; 26:1446-1454.
31. Cha S, Lu S, Johnson G, Knopp EA. Dynamic susceptibility contrast MR imaging: correlation of signal intensity changes with cerebral blood volume measurements. J Magn Reson Imaging 2000; 11:114-119.
32. Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Am J Neuroradiol 2007; 28:1078-1084.
33. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010; 9:906-920.